Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$47 Mln
P/E Ratio
--
P/B Ratio
0.35
Industry P/E
--
Debt to Equity
0
ROE
-0.5 %
ROCE
-49.67 %
Div. Yield
0 %
Book Value
19
EPS
-5.02
CFO
$-218.86 Mln
EBITDA
$-210.85 Mln
Net Profit
$-309.41 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Avalo Therapeutics (AVTX)
| -32.97 | -34.99 | -24.43 | -59.21 | -85.47 | -76.85 | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Avalo Therapeutics (AVTX)
| -18.22 | -99.25 | -35.61 | -51.02 | 66.87 | 0.93 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.90 | 9,808.03 | 20.22 | 23.13 | |
| 291.44 | 8,956.09 | 22.08 | 58.42 | |
| 26.70 | 9,559.25 | -- | -28.77 | |
| 104.01 | 10,030.35 | 30.81 | 14.16 |
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to... interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland. Address: 540 Gaither Road, Rockville, MD, United States, 20850 Read more
Chairman of the Board, President & CEO
Dr. Garry A. Neil M.D.
Chairman of the Board, President & CEO
Dr. Garry A. Neil M.D.
Headquarters
Rockville, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Avalo Therapeutics Inc (AVTX) stood at $ 151 Mln as on 31-Dec-24
The share price of Avalo Therapeutics Inc (AVTX) is $4.98 (NASDAQ) as of 23-Apr-2025 12:32 EDT. Avalo Therapeutics Inc (AVTX) has given a return of -85.47% in the last 3 years.
Avalo Therapeutics Inc (AVTX) has a market capitalisation of $ 47 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Avalo Therapeutics Inc (AVTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Avalo Therapeutics Inc (AVTX) and enter the required number of quantities and click on buy to purchase the shares of Avalo Therapeutics Inc (AVTX).
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland. Address: 540 Gaither Road, Rockville, MD, United States, 20850
The CEO & director of Dr. Garry A. Neil M.D.. is Avalo Therapeutics Inc (AVTX), and CFO & Sr. VP is Dr. Garry A. Neil M.D..
There is no promoter pledging in Avalo Therapeutics Inc (AVTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Avalo Therapeutics Inc. (AVTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-50.06
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-7965.76
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Avalo Therapeutics Inc (AVTX) was $0 Mln.
$0.11
(
